Response to Letter to Editor Regarding “Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma”
Volume 26, Issue 12, December 2020, Pages e335-e336
Previous article in issueNext article in issue
Recommended articlesCiting articles (0)
© 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
Recommended articlesCiting articlesArticle Metrics
留言 (0)